Research Topics
Species | Allan SnidermanSummaryAffiliation: McGill University Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Insights from apoB: from better diagnosis & therapy to the Medusa HypothesisAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
Atheroscler Suppl 5:19-24. 2004..The Medusa Hypothesis puts forward a common pathophysiology for the complex and biologically diverse array of factors that have been associated with vascular disease...
Of mice and men (and women) and the acylation-stimulating protein pathwayA D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada
Curr Opin Lipidol 11:291-6. 2000..Accordingly, to understand the impact of any intervention on energy storage and release by adipocytes, the effects of both insulin and ASP must be taken into account...
Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to goAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
Curr Opin Endocrinol Diabetes Obes 14:116-23. 2007..Getting it right means getting the target for therapy right, however. The article examines the criteria that should be used to make this choice...
Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithmAllan D Sniderman
Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
Curr Opin Lipidol 15:433-8. 2004..The second is to present a diagnostic algorithm for the apolipoprotein B100 dyslipidemias based on triglyceride and apoB...
Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesisAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Division of Cardiology, McGill University Health Science Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada
Int J Epidemiol 36:220-5. 2007....
Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular diseaseA D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
J Intern Med 259:455-61. 2006..0%. Thus, using the conventional cholesterol ratios rather than the apoB/apoA-I ratio results in frequent and substantial error in the estimation of the lipoprotein-related risk of vascular disease...
If apoB is so good, why isn't everybody measuring it? One reason why we need The Netherlands Journal of Medicine!A D Sniderman
Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
Neth J Med 63:232-5. 2005
Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formulaAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
Clin Biochem 36:499-504. 2003
Is there value in liver function test and creatine phosphokinase monitoring with statin use?Allan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
Am J Cardiol 94:30F-34F. 2004..The conclusion that follows, based on the evidence in hand, is that although these programs were appropriate at the time statins were introduced, they are not appropriate now...
High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterolA D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
Am J Cardiol 87:792-3, A8. 2001..Measurment of apolipoprotein B is the key to diagnosis and such patients should be considered for statin therapy...
Hypertriglyceridemic hyperapoB in type 2 diabetesAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Canada
Diabetes Care 25:579-82. 2002..In particular, there are few data on apoB levels in these patients. Moreover, most reports have focused on mean lipoprotein levels and consequently there is little information on the frequencies of the various dyslipidemic phenotypes...
Lipoprotein(a) and atherogenesis: a puzzle inside a riddle within an enigmaAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Que
Clin Invest Med 25:89-91. 2002
How, when, and why to use apolipoprotein B in clinical practiceAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
Am J Cardiol 90:48i-54i. 2002....
Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cellsAllan D Sniderman
Mike Rosenbloom Laboratories for Cardiovascular Research, Cardiovascular Genetics Laboratory, McGill University, Montreal, Canada
J Lipid Res 44:527-32. 2003..They also point to physiologically important, although still only partially understood, metabolic relationships amongst hepatic apoB-100 secretion, cholesterol efflux, and bile acid synthesis...
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatmentA D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, QC, Canada
Lancet 361:777-80. 2003
Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1Jessica Smith
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Canada
Clin Endocrinol (Oxf) 65:667-72. 2006..42, P = 0.004 and R = 0.48, P = 0.003) and Indian women (R = 0.46, P = 0.05 and R = 0.59, P = 0.01). CONCLUSION: Visfatin concentrations may be related to HDL metabolism in Asian Indian immigrants...
Levels of lipids and apolipoproteins in three culturesAmirreza Solhpour
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec H3A 1A1, Canada
Atherosclerosis 207:200-7. 2009..The objective of this study was to demonstrate the additional information that can be acquired by comparing the major plasma lipids and apolipoproteins amongst adult male and female Swedes, Iranians and Americans...
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?Allan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Vic Hosp, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
J Clin Lipidol 4:152-5. 2010..Rather, non-HDL-C appears to be an indirect way of estimating apoB. We argue that we should integrate the information from non-HDL-C and apoB for better risk assessment and a better target of therapy...
Diagnosis and treatment of apolipoprotein B dyslipoproteinemiasAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
Nat Rev Endocrinol 6:335-46. 2010..Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids...
Non-HDL C equals apolipoprotein B: except when it does not!Allan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal, Quebec, Canada
Curr Opin Lipidol 21:518-24. 2010..Canada has chosen to do so. What Europe and America decide remains to be seen...
Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severityB Charles Solymoss
Montreal Heart Institute, McGill University Health Centre, Montreal, Quebec, Canada
Am J Cardiol 93:159-64. 2004..Therefore, the MS score provides a clinically useful index of MS severity and the associated atherosclerotic risk factor profile. It also correlates with the angiographic severity of CAD and its clinical complications...
Targets for LDL-lowering therapyAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada
Curr Opin Lipidol 20:282-7. 2009..The conventional approach is restricted to a comparison of in-trial data. Although essential, this overlooks the issue as to which marker better identifies residual risk after any particular treatment regimen...
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendationsJacques Genest
McGill University Health Centre, Montreal, Canada
Can J Cardiol 25:567-79. 2009..The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult...
Body composition and the apoB/apoA-I ratio in migrant Asian Indians and white Caucasians in CanadaJessica Smith
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
Clin Sci (Lond) 111:201-7. 2006..It also relates differences in body fat distribution to differences in the apoB/apoA-I ratio, providing at least part of the answer as to why South Asians may be at increased risk of vascular disease...
Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein loweringAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7, 22, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, H3A 1A1 Canada
J Clin Lipidol 6:303-9. 2012..It follows that definitive evidence supporting maximal lowering of LDL-C or maximal dose of statins is still lacking and guidelines, if they are to be evidence-based, should acknowledge this uncertainty...
ApoB versus non-HDL-C: what to do when they disagreeAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, Royal Victoria Hospital MUHC, Quebec, Canada
Curr Atheroscler Rep 11:358-63. 2009..These examples establish that apoB and non-HDL-C are not clinical equivalents...
The adipocyte life cycle hypothesisJessica Smith
The Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Clin Sci (Lond) 110:1-9. 2006..This hypothesis may explain a variety of previously unanswered clinical puzzles such as the vulnerability of many peoples from South East Asia to the adverse metabolic consequences of obesity...
Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearanceKatherine Cianflone
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue, West Montreal, Quebec H3A 1A1, Canada
J Lipid Res 45:124-31. 2004..Plasma ASP may be useful as a fasting variable that will provide additional information regarding ppTG and NEFA clearance...
Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profileLeslie Price
McGill University Health Centre, Montreal, Quebec
Can J Cardiol 23:233-4. 2007..It suggests that the characteristics of the valve are more critical than the patient's level of LDL-C...
Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein BAllan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, H7 22, Royal Victoria Hospital, MUHC, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
J Clin Lipidol 1:256-63. 2007..Our objective was to develop a simple algorithm that could be applied in routine clinical practice to diagnose type III hyperlipoproteinemia based on plasma total cholesterol, triglyceride and apolipoprotein (Apo) B...
Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitationBenoit de Varennes
McGill University Health Center, Montreal, Quebec, Canada
Circulation 119:2837-43. 2009..Management of severe ischemic mitral regurgitation remains difficult with disappointing early and intermediate-term surgical results of valve repair...
Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?Allan Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
Clin Sci (Lond) 113:365-7. 2007..The key feature of this model of common complex disease is that it posits testable faults in definable metabolic pathways, which supply the genetic underpinning of the disorder...
Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis StudyNaveed Sattar
Section of Vascular Biochemistry, North Glasgow Hospitals University NHS Trust, Glasgow Royal Infirmary, Glasgow, UK
Circulation 110:2687-93. 2004..Our data suggest that apoB is a better candidate risk parameter than NHDLC for identifying a subgroup of individuals with or without MetS with elevated cardiovascular risk...
The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysisAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, Royal Victoria Hospital, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Curr Atheroscler Rep 9:261-5. 2007..Appreciating these distinctions should allow appropriate use of the apoB/apoA-I ratio as a simple, single, summary index of the lipoprotein-related risk of vascular disease...
The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular riskDestry Sulkes
MedsiteCME, New York, New York, USA
Am J Cardiol 101:828-42. 2008
Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?Ingmar Jungner
Department of Medicine, Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden
Am J Cardiol 97:943-6. 2006..The strongest single lipoprotein-related risk factor was the apo-B/apo-A-I ratio. In conclusion, these results provide further confirmation of the importance of determining apo-B and apo-A-I in routine clinical practice...
Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)Ken Williams
Department of Medicine, University of Texas Health Science Center, San Antonio, USA
Circulation 108:2312-6. 2003..This may provide new insight into why apoB is a better predictor of vascular risk than LDLC...
Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thingAllan D Sniderman
Diabetes Care 26:2207-8. 2003
Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic riskAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, , Canada
Am J Cardiol 91:1173-7. 2003....
The apoB/apoA-I ratio and insulin resistance: sorting out the metabolic syndromeAllan D Sniderman
Eur Heart J 28:2563-4. 2007
Non-HDL cholesterol and apoB in dyslipidaemiaAllan D Sniderman
The Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
Clin Sci (Lond) 114:149-55. 2008..It follows that correlation is not adequate as a sole judge of equivalence of laboratory parameters...
Identification of a novel C5L2 variant (S323I) in a French Canadian family with familial combined hyperlipemiaMichel Marcil
, , Y2186, 2725 Chemin Ste Foy, Ste Foy, , G1V 4G5
Arterioscler Thromb Vasc Biol 26:1619-25. 2006..CONCLUSIONS: The S323I variant may alter C5L2 function and might be one molecular basis contributing to familial combined hyperlipidemia...
Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohortAndré J Tremblay
Lipid Research Center, CHUQ Research Center, Québec Québec, Canada
Clin Biochem 40:25-9. 2007..To examine the relationship between plasma triglycerides (TG) to HDL-cholesterol (HDL-C) or HDL apo A-I...
Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemiaEwoud ter Avest
Department of Medicine, Division of General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
Clin Sci (Lond) 112:131-9. 2007..However, aging-related post-maturation increases in adipose tissue mass also appear to contribute to an aggravation and/or modulation of this genetically determined apoB overproduction...
Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner isAllan D Sniderman
Circulation 112:3366-7. 2005
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndromeAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada
Curr Opin Lipidol 18:633-7. 2007..Therefore, our objective is to elucidate how apolipoprotein B and apolipoprotein A-I amplify evidence of the interactions amongst metabolic syndrome, insulin resistance, abdominal obesity, and vascular risk...
Apolipoprotein A1 and BAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Clin Lab Med 26:733-50. 2006....
What do we (not) know about apoB, type 2 diabetes and obesity?J Smith
Department of Dietetics and Human Nutrition, McGill University, Montreal, Que, Canada
Diabetes Res Clin Pract 69:99-101. 2005
Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular diseaseAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
Am J Cardiol 100:217-21. 2007..In conclusion, it appears that not all of the effects of age are irreversible. therefore, outcomes with early prevention might be much more favorable than usually assumed...
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary riskGoran Walldius
King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
Clin Chem Lab Med 42:1355-63. 2004..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
We must prevent disease, not predict eventsAllan D Sniderman
J Am Coll Cardiol 52:300-1. 2008
Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob miceZhunan Xia
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Montreal, Quebec H3A 1A1, Canada
J Biol Chem 277:45874-9. 2002..9 ml/h; ob/ob, 102 +/- 4.5 ml/h; p < 0.01; wild type, 144 +/- 8.9 ml/h). These results suggest that the ASP regulation of energy storage may influence energy expenditure and dynamic metabolic balance...
Risk factors for cardiovascular disease in womenAllan D Sniderman
JAMA 294:2843-4; author reply 2844. 2005
Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetesFrederico G S Toledo
Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, School of Medicine, Pennsylvania, USA
Diabetes Care 29:1845-50. 2006....
Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3Antonie J van Oostrom
Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands
Am J Clin Nutr 79:510-5. 2004..After ingestion of fat without glucose, the lack of insulin response may lead to C3-mediated peripheral FFA trapping, which probably serves as a backup system in case of insufficient or inefficient insulin-dependent FFA trapping...
Age as a modifiable risk factor for cardiovascular diseaseAllan D Sniderman
Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
Lancet 371:1547-9. 2008
ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytesMay Faraj
Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Montreal, Canada
J Lipid Res 45:657-66. 2004....
